138 related articles for article (PubMed ID: 6375864)
1. Chemosensitizers counteracting acquired resistance to anthracyclines and vinca alkaloids in vivo. A new treatment principle.
Skovsgaard T; Danø K; Nissen NI
Cancer Treat Rev; 1984 Mar; 11 Suppl A():63-72. PubMed ID: 6375864
[No Abstract] [Full Text] [Related]
2. Interactions among membrane transport systems: anthracyclines, calcium antagonists and anti-estrogens.
Kessel D
Biochem Pharmacol; 1986 Aug; 35(16):2825-6. PubMed ID: 2943288
[No Abstract] [Full Text] [Related]
3. [Reversal of acquired resistance to vinca alkaloids and anthracycline antibiotics by calcium channel blockers and calmodulin inhibitors].
Tsuruo T
Gan To Kagaku Ryoho; 1984 Mar; 11(3 Pt 2):750-9. PubMed ID: 6585181
[TBL] [Abstract][Full Text] [Related]
4. Non-antitumor vinca alkaloids reverse multidrug resistance in P388 leukemia cells in vitro.
Inaba M; Nagashima K
Jpn J Cancer Res; 1986 Feb; 77(2):197-204. PubMed ID: 3082832
[TBL] [Abstract][Full Text] [Related]
5. Reversal of acquired resistance to vinca alkaloids and anthracycline antibiotics.
Tsuruo T
Cancer Treat Rep; 1983 Oct; 67(10):889-94. PubMed ID: 6354436
[TBL] [Abstract][Full Text] [Related]
6. Experimental basis and clinical experience with non-cross-resistant combinations in solid tumours.
Seeber S; Dimitriadis K; Schütte J; Schmidt CG
Cancer Treat Rev; 1984 Mar; 11 Suppl A():55-61. PubMed ID: 6329514
[TBL] [Abstract][Full Text] [Related]
7. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells.
Zamora JM; Pearce HL; Beck WT
Mol Pharmacol; 1988 Apr; 33(4):454-62. PubMed ID: 3162758
[TBL] [Abstract][Full Text] [Related]
8. Cross resistance between vinca alkaloids and anthracyclines in Ehrlich ascites tumor in vivo.
Dano K
Cancer Chemother Rep; 1972 Dec; 56(6):701-8. PubMed ID: 4660629
[No Abstract] [Full Text] [Related]
9. o-Methylation on anthracyclines and anthracyclinones. New o-methyl ethers of daunorubicin and its analogues.
Cassinelli G; Di Matteo F; Forenza S; Ripamonti MC; Ruggieri D; Vigevani A; Arcamone F
Farmaco Sci; 1982 Aug; 37(8):501-13. PubMed ID: 6957317
[TBL] [Abstract][Full Text] [Related]
10. Resistance to anthrapyrazoles and anthracyclines in multidrug-resistant P388 murine leukemia cells: reversal by calcium blockers and calmodulin antagonists.
Klohs WD; Steinkampf RW; Havlick MJ; Jackson RC
Cancer Res; 1986 Sep; 46(9):4352-6. PubMed ID: 3460695
[TBL] [Abstract][Full Text] [Related]
11. Reversal of multidrug resistance by non-antitumor anthracycline analogs.
Inaba M; Nagashima K; Sakurai Y; Fukui M; Yanagi Y
Gan; 1984 Dec; 75(12):1049-52. PubMed ID: 6597118
[TBL] [Abstract][Full Text] [Related]
12. Anthracycline resistance in P388 murine leukemia and its circumvention by calcium antagonists.
Kessel D; Wilberding C
Cancer Res; 1985 Apr; 45(4):1687-91. PubMed ID: 3919944
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of resistance to anthracyclines and vinca alkaloids.
Danø K; Skovsgaard T; Nissen NI; Friche E; Di Marco A
Prog Clin Biol Res; 1983; 132C():231-46. PubMed ID: 6579564
[TBL] [Abstract][Full Text] [Related]
14. Sensitivity to anthracyclines in P388/dx leukaemia cells.
Bossa R; Dasdia T; Galatulas I; Zunino F
Anticancer Res; 1986; 6(5):1037-9. PubMed ID: 3099628
[TBL] [Abstract][Full Text] [Related]
15. Arugomycin, a new anthracycline antibiotic. III. Biological activities of arugomycin and its analogues obtained by chemical degradation and modification.
Shimosaka A; Kawai H; Hayakawa Y; Komeshima N; Nakagawa M; Seto H; Otake N
J Antibiot (Tokyo); 1987 Sep; 40(9):1283-91. PubMed ID: 3479414
[TBL] [Abstract][Full Text] [Related]
16. Increased plasma membrane traffic in daunorubicin resistant P388 leukaemic cells. Effect of daunorubicin and verapamil.
Sehested M; Skovsgaard T; van Deurs B; Winther-Nielsen H
Br J Cancer; 1987 Dec; 56(6):747-51. PubMed ID: 3435701
[TBL] [Abstract][Full Text] [Related]
17. Interactions between calcium antagonists, calcium fluxes and anthracycline transport.
Kessel D; Wilberding C
Cancer Lett; 1984 Nov; 25(1):97-101. PubMed ID: 6097354
[TBL] [Abstract][Full Text] [Related]
18. [Characteristics of anthracycline-resistant strains of P388 leukemia].
Goncharova SA; Demidova NS; Shiriaeva OA; Shevtsova VN; Konovalova NP
Eksp Onkol; 1987; 9(4):42-7. PubMed ID: 3678124
[TBL] [Abstract][Full Text] [Related]
19. Factors governing the modulation of vinca-alkaloid resistance in doxorubicin-resistant cells by the calmodulin inhibitor trifluoperazine.
Ganapathi R; Grabowski D; Schmidt H
Biochem Pharmacol; 1986 Feb; 35(4):673-8. PubMed ID: 3947398
[TBL] [Abstract][Full Text] [Related]
20. Calmodulin inhibitor trifluoperazine selectively enhances cytotoxic effects of strong vs weak DNA binding antitumor drugs in doxorubicin-resistant P388 mouse leukemia cells.
Ganapathi R; Grabowski D; Schmidt H; Seshadri R; Israel M
Biochem Biophys Res Commun; 1985 Sep; 131(2):912-9. PubMed ID: 2932108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
